

Wright Medical Group, Inc.
Reconciliation of Net Sales to Net Sales Excluding the Impact of Foreign Currency
(dollars in thousands--unaudited)

	Three Months Ended		Twelve Months Ended	
	December 31, 2009		December 31, 2009	
	International	Total	International	Total
	Net Sales	Net Sales	Net Sales	Net Sales
Net sales, as reported	\$ 51,621	\$ 129,928	\$ 187,921	\$ 487,508
Currency impact as compared to prior period	(3,460)	(3,460)	2,959	2,959
Net sales, excluding the impact of foreign currency	\$ 48,161	\$ 126,468	\$ 190,880	\$ 490,467

Wright Medical Group, Inc.
Reconciliation of As Reported Results to Non-GAAP Financial Measures
(in thousands, except per share data--unaudited)

	Three Months Ended		Twelve Months Ended	
	December 31, 2009	December 31, 2008	December 31, 2009	December 31, 2008
Operating Income				
Operating income, as reported	\$ 4,500	\$ 10,027	\$ 23,951	\$ 22,413
<i>Reconciling items impacting Gross Profit:</i>				
Inventory step-up amortization	-	18	70	113
Non-cash, stock-based compensation	347	292	1,285	1,244
Total	347	310	1,355	1,357
<i>Reconciling items impacting Selling, General and Administrative expenses:</i>				
Non-cash, stock-based compensation	2,255	2,204	10,077	10,644
U.S. governmental inquiries	186	2,916	7,845	7,648
Write-down of international receivable	5,579	-	5,579	-
Appellate court decision	-	-	-	2,346
Total	8,020	5,120	23,501	20,638
<i>Reconciling items impacting Research and Development expenses:</i>				
Non-cash, stock-based compensation	389	517	1,829	1,613
<i>Other Reconciling Items:</i>				
Restructuring charges	2,553	1,110	3,544	6,705
Acquired in-process research and development	-	-	-	2,490
Total	2,553	1,110	3,544	9,195
Operating income, as adjusted	\$ 15,809	\$ 17,084	\$ 54,180	\$ 55,216
Operating income, as adjusted, as a percentage of net sales	12.2%	14.2%	11.1%	11.9%

Wright Medical Group, Inc.
Reconciliation of As Reported Results to Non-GAAP Financial Measures
(continued)

	<u>Three Months Ended</u>		<u>Twelve Months Ended</u>	
	<u>December 31, 2009</u>	<u>December 31, 2008</u>	<u>December 31, 2009</u>	<u>December 31, 2008</u>
Net Income				
(Loss) income before income taxes, as reported	\$ (223)	\$ 9,404	\$ 15,612	\$ 21,570
Non-cash, stock-based compensation	2,991	3,013	13,191	13,501
Restructuring charges	2,553	1,110	3,544	6,705
Inventory step-up amortization	-	18	70	113
U.S. governmental inquiries	186	2,916	7,845	7,648
Write-down of international receivable	5,579	-	5,579	-
CTA write-off	2,643	-	2,643	-
Appellate court decision (including interest)	-	-	-	2,638
Acquired in-process research and development	-	-	-	2,490
Income before income taxes, as adjusted	<u>13,729</u>	<u>16,461</u>	<u>48,484</u>	<u>54,665</u>
(Benefit) provision for income taxes, as reported	(2,458)	12,095	3,481	18,373
Non-cash, stock-based compensation	896	576	3,901	3,674
Restructuring charges	2,882	1,275	3,269	3,451
Inventory step-up amortization	-	7	27	44
U.S. governmental inquiries	(208)	1,122	2,789	2,987
Write-down of international receivable	1,817	-	1,817	-
CTA write-off	-	-	-	-
Appellate court decision	-	-	-	1,030
Acquired in-process research and development	-	-	-	-
Valuation allowance for French NOL's	-	(11,223)	-	(11,223)
Provision for income taxes, as adjusted	<u>2,929</u>	<u>3,852</u>	<u>15,284</u>	<u>18,336</u>
Effective tax rate, as adjusted	<u>21.3%</u>	<u>23.4%</u>	<u>31.5%</u>	<u>33.5%</u>
Net income, as adjusted	<u>\$ 10,800</u>	<u>\$ 12,609</u>	<u>\$ 33,200</u>	<u>\$ 36,329</u>

	<u>Three Months Ended</u>		<u>Three Months Ended</u>	
	<u>December 31, 2009</u>		<u>December 31, 2008</u>	
	<u>As Reported</u>	<u>As Adjusted</u>	<u>As Reported</u>	<u>As Adjusted</u>
Basic net income (loss)	\$ 2,235	\$ 10,800	\$ (2,691)	\$ 12,609
Interest expense on convertible notes	N/A	935	N/A	935
Diluted net income (loss)	\$ 2,235	\$ 11,735	\$ (2,691)	\$ 13,544
Basic shares	37,470	37,470	37,198	37,198
Dilutive effect of stock options and restricted shares	248	248	-	198
Dilutive effect of convertible notes	N/A	6,126	-	6,126
Diluted shares	<u>37,718</u>	<u>43,844</u>	<u>37,198</u>	<u>43,522</u>
Net income (loss) per share, diluted	<u>\$ 0.06</u>	<u>\$ 0.27</u>	<u>\$ (0.07)</u>	<u>\$ 0.31</u>

Wright Medical Group, Inc.
Reconciliation of As Reported Results to Non-GAAP Financial Measures
(continued)

	<u>Twelve Months Ended</u>		<u>Twelve Months Ended</u>	
	<u>December 31, 2009</u>		<u>December 31, 2008</u>	
	<u>As Reported</u>	<u>As Adjusted</u>	<u>As Reported</u>	<u>As Adjusted</u>
Basic net income	\$ 12,131	\$ 33,200	\$ 3,197	\$ 36,329
Interest expense on convertible notes	N/A	3,740	N/A	3,741
Diluted net income	\$ 12,131	\$ 36,940	\$ 3,197	\$ 40,070
Basic shares	37,366	37,366	36,933	36,933
Dilutive effect of stock options and restricted shares	77	77	468	468
Dilutive effect of convertible notes	-	6,126	-	6,126
Diluted shares	37,443	43,569	37,401	43,527
Net income per share, diluted	<u>\$ 0.32</u>	<u>\$ 0.85</u>	<u>\$ 0.09</u>	<u>\$ 0.92</u>
	<u>Three Months Ended</u>		<u>Twelve Months Ended</u>	
	<u>December 31,</u>	<u>December 31,</u>	<u>December 31,</u>	<u>December 31,</u>
	<u>2009</u>	<u>2008</u>	<u>2009</u>	<u>2008</u>
Net Income per Diluted Share				
Net income (loss), as reported, per diluted share	\$ 0.06	\$ (0.07)	\$ 0.32	\$ 0.09
Interest expense on convertible notes	0.02	0.02	0.09	0.09
Dilutive effect of convertible notes	(0.01)	0.01	(0.05)	(0.01)
Non-cash, stock-based compensation	0.05	0.06	0.21	0.23
Restructuring charges	(0.01)	(0.00)	0.01	0.07
Inventory step-up amortization	-	0.00	0.00	0.00
U.S. governmental inquiries	0.01	0.04	0.12	0.11
Write-down of international receivable	0.09	-	0.09	-
CTA write-off	0.06	-	0.06	-
Appellate court decision	-	-	-	0.04
Acquired in-process research and development	-	-	-	0.06
Valuation allowance for French NOL's	-	0.26	-	0.26
Net income, as adjusted, per diluted share	<u>\$ 0.27</u>	<u>\$ 0.31</u>	<u>\$ 0.85</u>	<u>\$ 0.92</u>